Fiztasovimab, CAS 2467411-25-0

Product Description: Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV[1].

Applications: COVID-19-anti-virus

Formula: N/A

References: [1]Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11(6):707-716.

CAS Number: 2467411-25-0

Molecular Weight: N/A

Compound Purity: 96.49

Research Area: Infection

Solubility: 10 mM in DMSO

Target: CMV

• Artikelnummer: MEXHY-P99621-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99621-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated